MarketCapExport financials
Cardiovascular Systems (CSII)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Cardiovascular Systems Balance Sheet 2022-2009 | CSII
Brief overview of Cardiovascular Systems's balance sheet strength
The balance sheet is assessed across five available annual reports spanning 2018 to 2022.
Total assets increased by +58.7%, from $203.4 million to $322.7 million. A CAGR near 12.2% points to substantial expansion.
Liability growth of +6.3% trailed asset growth of +58.7%. The funding structure became more resilient.
The equity ratio reached 77.3% from 66.1%. A high capital share reduces dependence on liabilities.
Net debt moved below zero to -$64.6 million, reflecting surplus cash over debt.
The cash reserve occupies 20.6% of the balance sheet, previously 57.2%. It is one marker of short-term resilience.
Retained earnings are negative at -$423.7 million. This reduces the formal capital cushion, although large shareholder returns may have contributed.
Overall picture
Cardiovascular Systems's balance sheet looks resilient: assets are supported by substantial equity, while debt does not overwhelm financial flexibility.
Annual Balance Sheet Cardiovascular Systems
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-64.6 M | -68.9 M | - | -53.3 M | -95.2 M | -86.8 M | -60.6 M | -83.8 M | -124 M | -55.3 M | -18 M | -9.02 M | - | - |
Long Term Debt |
1.33 M | 1.72 M | - | - | - | - | - | - | - | 7.47 M | 12.8 M | 8.33 M | - | - |
Long Term Debt Current |
526 K | 487 K | - | - | - | - | - | - | 2.4 M | 5.1 M | 4.68 M | 3.81 M | - | - |
Total Non Current Liabilities |
- | - | - | 28.3 M | 31.4 M | 34.6 M | 6.01 M | 2 M | 117 K | 7.65 M | 13.1 M | 9.94 M | - | - |
Total Current Liabilities |
40 M | 54.6 M | 44.5 M | 42.3 M | 37.5 M | 41 M | 35.5 M | 29.9 M | 29.7 M | 22.4 M | 17.9 M | 15.2 M | - | - |
Total Liabilities |
73.2 M | 81.6 M | 70.7 M | 70.6 M | 68.9 M | 75.6 M | 41.5 M | 31.9 M | 29.8 M | 30.1 M | 30.9 M | 25.1 M | - | - |
Deferred Revenue |
2.11 M | 2.4 M | 1.87 M | 1.76 M | 1.24 M | - | - | - | 59 K | 156 K | - | - | - | - |
Retained Earnings |
-424 M | -381 M | -363 M | -330 M | -328 M | -329 M | -327 M | -271 M | -239 M | -203 M | -179 M | -162 M | - | - |
Total Assets |
323 M | 353 M | 340 M | 219 M | 203 M | 194 M | 142 M | 171 M | 182 M | 96.9 M | 63.1 M | 46.8 M | - | - |
Cash and Cash Equivalents |
66.4 M | 71.1 M | 185 M | 74.2 M | 116 M | 108 M | 60.6 M | 83.8 M | 127 M | 67.9 M | 35.5 M | 21.2 M | 23.7 M | 33.4 M |
Book Value |
249 M | 271 M | 269 M | 148 M | 134 M | 118 M | 101 M | 139 M | 152 M | 66.8 M | 32.2 M | 21.6 M | - | - |
Total Shareholders Equity |
249 M | 271 M | 269 M | 148 M | 134 M | 118 M | 101 M | 139 M | 152 M | 66.8 M | 32.2 M | 21.6 M | 17.7 M | 30.3 M |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet Cardiovascular Systems
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
1.11 M | 1.22 M | 1.11 M | 1.43 M | 1.52 M | 1.64 M | 1.52 M | 1.64 M | 1.83 M | 1.72 M | 1.94 M | 2.05 M | 175 K | 306 K | 175 K | 306 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.74 M | - | 8.85 M | 10.4 M | 11.6 M | 10.4 M | 14.1 M | 15.4 M | 8.44 M | 15.4 M | 8.44 M | 8.33 M | 8.33 M |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 112 K | 123 K | 5.9 M | 123 K | 9.09 M | 10.6 M | 11.8 M | 10.6 M | 14.3 M | 15.8 M | 9.86 M | 15.8 M | 9.86 M | 9.94 M | 9.94 M |
Total Liabilities |
72.1 M | 69.9 M | 72.1 M | 70.5 M | 66.9 M | 69.1 M | 66.9 M | 69.1 M | 76.5 M | 81.6 M | 75.1 M | 73.3 M | 80.9 M | 75 M | 80.9 M | 69.6 M | 68.6 M | 66.3 M | 68.6 M | 68.3 M | 66.1 M | 70.3 M | 66.1 M | 73.4 M | 46.6 M | 35.4 M | 46.6 M | 43.2 M | 30 M | 31.8 M | 30 M | 35.9 M | 32.5 M | 33.9 M | 32.5 M | 29.2 M | 24.9 M | 29.8 M | 24.9 M | 29 M | 27.5 M | 31.1 M | 27.5 M | 30.5 M | 30.1 M | 25 M | 30.1 M | 25 M | 25.1 M | 25.1 M |
Deferred Revenue |
525 K | 694 K | 525 K | 2.81 M | 2.72 M | 2.49 M | 2.72 M | 2.49 M | 2.26 M | 2.4 M | 2.08 M | 2.09 M | 1.66 M | 1.71 M | 1.66 M | 1.61 M | 1.52 M | 1.25 M | 1.52 M | 1.55 M | 1.1 M | 1.24 M | 1.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-443 M | -436 M | -443 M | -414 M | -404 M | -395 M | -404 M | -395 M | -376 M | -381 M | -369 M | -369 M | -345 M | -341 M | -345 M | -331 M | -331 M | -331 M | -331 M | -331 M | -332 M | -331 M | -332 M | -330 M | -328 M | -329 M | -328 M | -323 M | -300 M | -285 M | -300 M | -263 M | -252 M | -247 M | -252 M | -229 M | -219 M | -211 M | -219 M | -196 M | -190 M | -184 M | -190 M | -175 M | -170 M | -166 M | -170 M | -166 M | -162 M | -162 M |
Total Assets |
312 M | 312 M | 312 M | 324 M | 326 M | 332 M | 326 M | 332 M | 347 M | 353 M | 349 M | 342 M | 224 M | 217 M | 224 M | 211 M | 207 M | 200 M | 207 M | 195 M | 190 M | 190 M | 190 M | 187 M | 159 M | 138 M | 159 M | 145 M | 151 M | 162 M | 151 M | 179 M | 181 M | 182 M | 181 M | 185 M | 181 M | 95.1 M | 181 M | 99 M | 56.6 M | 60.1 M | 56.6 M | 49.8 M | 52 M | 48.3 M | 52 M | 48.3 M | 46.8 M | 46.8 M |
Cash and Cash Equivalents |
59.8 M | 62.8 M | 59.8 M | 67 M | 65.9 M | 66.9 M | 65.9 M | 66.9 M | 75.3 M | 71.1 M | 73.8 M | 92.7 M | 65.5 M | 58.9 M | 65.5 M | 115 M | 119 M | 113 M | 119 M | 109 M | 107 M | 105 M | 107 M | 103 M | 79.3 M | 58.2 M | 79.3 M | 62.2 M | 65.3 M | 76.7 M | 62.2 M | 93.5 M | 101 M | 116 M | 101 M | 146 M | 147 M | 63.2 M | 147 M | 69.9 M | 29.2 M | 32.2 M | 29.2 M | 22.5 M | 24.6 M | 22.7 M | 24.6 M | 22.7 M | 24.6 M | 22.7 M |
Book Value |
239 M | 242 M | 239 M | 253 M | 260 M | 263 M | 260 M | 263 M | 270 M | 271 M | 274 M | 268 M | 143 M | 142 M | 143 M | 142 M | 139 M | 134 M | 139 M | 126 M | 124 M | 120 M | 124 M | 113 M | 112 M | 103 M | 112 M | 102 M | 121 M | 131 M | 121 M | 143 M | 148 M | 148 M | 148 M | 156 M | 156 M | 65.3 M | 156 M | 70 M | 29.2 M | 29 M | 29.2 M | 19.3 M | 21.9 M | 23.3 M | 21.9 M | 23.3 M | 21.6 M | 21.6 M |
Total Shareholders Equity |
239 M | 242 M | 239 M | 253 M | 260 M | 263 M | 260 M | 263 M | 270 M | 263 M | 274 M | 268 M | 143 M | 142 M | 143 M | 142 M | 139 M | 134 M | 139 M | 126 M | 124 M | 120 M | 124 M | 113 M | 112 M | 103 M | 112 M | 102 M | 121 M | 131 M | 121 M | 143 M | 148 M | 148 M | 148 M | 156 M | 156 M | 65.3 M | 156 M | 70 M | 29.2 M | 29 M | 29.2 M | 19.3 M | 21.9 M | 23.3 M | 21.9 M | 23.3 M | 21.6 M | 21.6 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of Cardiovascular Systems, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Medical devices
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Align Technology
ALGN
|
$ 164.4 | 3.16 % | $ 11.9 B |  USA |
 |
Abbott Laboratories
ABT
|
$ 110.03 | -3.18 % | $ 192 B | USA |
 |
Bio-Rad Laboratories
BIO
|
$ 382.08 | 3.5 % | $ 10.4 B | USA |
 |
EDAP TMS S.A.
EDAP
|
- | - | $ 162 M |  France |
 |
Edwards Lifesciences Corporation
EW
|
$ 102.08 | 1.29 % | $ 59.7 B | USA |
 |
Alphatec Holdings
ATEC
|
$ 7.44 | -4.62 % | $ 1.12 B | USA |
 |
Avinger
AVGR
|
- | -20.74 % | $ 369 K | USA |
 |
Medtronic PLC
MDT
|
$ 101.83 | -2.9 % | $ 131 B | USA |
 |
ThermoGenesis Holdings
THMO
|
- | -25.84 % | $ 171 K | USA |
 |
MiMedx Group
MDXG
|
$ 3.31 | 0.91 % | $ 489 M | USA |
 |
Talis Biomedical Corporation
TLIS
|
- | 3.55 % | $ 7.96 M | USA |
 |
Cognyte Software Ltd.
CGNT
|
$ 8.1 | 0.06 % | $ 591 M |  Israel |
 |
Myomo
MYO
|
$ 1.21 | 1.68 % | $ 50.6 M | USA |
 |
CONMED Corporation
CNMD
|
$ 51.44 | -2.42 % | $ 1.6 B | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
$ 0.24 | -3.95 % | $ 15.5 M | Israel |
 |
Penumbra
PEN
|
$ 319.32 | -0.59 % | $ 12.4 B | USA |
 |
Viveve Medical
VIVE
|
- | -15.35 % | $ 1.71 M | USA |
 |
Insulet Corporation
PODD
|
$ 146.61 | -6.09 % | $ 10.3 B | USA |
 |
Smith & Nephew plc
SNN
|
$ 31.16 | -2.72 % | $ 27 B |  Britain |
 |
Stryker Corporation
SYK
|
$ 325.34 | -2.9 % | $ 124 B | USA |
 |
Tactile Systems Technology
TCMD
|
$ 26.03 | -0.83 % | $ 595 M | USA |
 |
TELA Bio
TELA
|
$ 0.82 | 5.24 % | $ 38.5 M | USA |
 |
TransMedics Group
TMDX
|
$ 87.58 | 26.96 % | $ 2.98 B | USA |
 |
SmileDirectClub
SDC
|
- | -53.45 % | $ 9.71 M | USA |
 |
Tandem Diabetes Care
TNDM
|
$ 16.63 | -7.59 % | $ 1.13 B | USA |
 |
Acutus Medical
AFIB
|
- | -26.83 % | $ 2.62 M | USA |
 |
BIOLASE
BIOL
|
- | -13.19 % | $ 166 K | USA |
 |
Viemed Healthcare
VMD
|
$ 9.14 | 1.39 % | $ 356 M | USA |
 |
SeaSpine Holdings Corporation
SPNE
|
- | 0.28 % | $ 270 M | USA |
 |
Varex Imaging Corporation
VREX
|
$ 18.45 | 0.03 % | $ 764 M | USA |
 |
Vivos Therapeutics
VVOS
|
$ 0.09 | -8.67 % | $ 925 K | USA |
 |
Apollo Endosurgery
APEN
|
- | - | $ 475 M | USA |
 |
Beyond Air
XAIR
|
$ 2.15 | -1.38 % | $ 17.8 B | USA |
 |
NuVasive
NUVA
|
- | - | $ 2.07 B | USA |
 |
Xtant Medical Holdings
XTNT
|
$ 0.28 | -5.0 % | $ 39.1 M | USA |
 |
Zimmer Biomet Holdings
ZBH
|
$ 105.43 | -1.42 % | $ 20.9 B | USA |
 |
Conformis
CFMS
|
- | - | $ 16.4 M | USA |
 |
ViewRay
VRAY
|
- | 1.54 % | $ 468 M | USA |
 |
Medigus Ltd.
MDGS
|
- | 10.28 % | $ 55.5 M | Israel |
 |
Cutera
CUTR
|
- | -10.19 % | $ 1.99 M | USA |
 |
Neovasc
NVCN
|
- | - | $ 111 M |  Canada |
 |
Vapotherm
VAPO
|
- | 6.72 % | $ 34 M | USA |
 |
Nevro Corp.
NVRO
|
- | - | $ 217 M | USA |
 |
Venus Concept
VERO
|
- | - | $ 726 K | USA |
 |
Eargo
EAR
|
- | - | $ 10.2 M | USA |
 |
Sientra
SIEN
|
- | -16.59 % | $ 10.3 M | USA |
 |
Silk Road Medical, Inc
SILK
|
- | - | $ 1.07 B | USA |
 |
Surgalign Holdings
SRGA
|
- | -32.98 % | $ 1.68 M | USA |
 |
ShockWave Medical
SWAV
|
- | - | $ 12.3 B | USA |